The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
Open accessAbstract
BACKGROUND: We conducted a multinational, randomized study to compare radiotherapy alone with radiotherapy plus cetuximab, a monoclonal antibody against the epidermal growth factor receptor, in the treatment of locoregionally advanced squamous-cell carcinoma of the head and neck. METHODS: Patients with locoregionally advanced head and neck cancer were randomly assigned to treatment with high-dose radiotherapy alone (213 patients) or high-dose radiotherapy plus weekly cetuximab (211 patients) at an initial dose of 400 mg per square meter of body-surface area, followed by 250 mg per square meter weekly for the duration of radiotherapy. The primary end point was the duration of control of locoregional disease; secondary end points were overall survival, progression-free survival, the response rate, and safety. RESULTS: The median duration of locoregional control was 24.4 months among patients treated with cetuximab plus radiotherapy and 14.9 months among those given radiotherapy alone (hazard ratio for locoregional progression or death, 0.68; P=0.005). With a median follow-up of 54.0 months, the median duration of overall survival was 49.0 months among patients treated with combined therapy and 29.3 months among those treated with radiotherapy alone (hazard ratio for death, 0.74; P=0.03). Radiotherapy plus cetuximab significantly prolonged progression-free survival (hazard ratio for disease progression or death, 0.70; P=0.006). With the exception of acneiform rash and infusion reactions, the incidence of grade 3 or greater toxic effects, including mucositis, did not differ significantly between the two groups. CONCLUSIONS: Treatment of locoregionally advanced head and neck cancer with concomitant high-dose radiotherapy plus cetuximab improves locoregional control and reduces mortality without increasing the common toxic effects associated with radiotherapy to the head and neck. (ClinicalTrials.gov number, NCT00004227.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2017) · Springer eBooks · doi:10.1007/978-3-319-40618-3 · Cited by 17,242
ERBB receptors and cancer: the complexity of targeted inhibitors
Hynes, N. E., & Lane, H. A. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1609 · Cited by 3,313
Pignon, J. (2000) · The Lancet · doi:10.1016/s0140-6736(00)90011-0 · Cited by 2,543
Pocock, S. J., & Simon, R. (1975) · Biometrics · doi:10.2307/2529712 · Cited by 2,350
Vokes, E. E., Weichselbaum, R. R., Lippman, S. M., & Hong, W. K. (1993) · New England Journal of Medicine · doi:10.1056/nejm199301213280306 · Cited by 2,211
Adelstein, D. J., Li, Y., Adams, G. L., Wagner, H., Kish, J. A., Ensley, J. F., Schuller, D. E., & Forastiere, A. A. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.01.008 · Cited by 1,748
Fu, K. K., Pajak, T. F., Trotti, A., Jones, C. U., Spencer, S. A., Phillips, T. L., Garden, A. S., Ridge, J. A., Cooper, J. S., & Ang, K. K. (2000) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(00)00663-5 · Cited by 1,357
Self-citationStatus of Epidermal Growth Factor Receptor Antagonists in the Biology and Treatment of Cancer
Mendelsohn, J., & Baselga, J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.01.504 · Cited by 1,255
Self-citationAng, K. K., Berkey, B. A., Tu, X., Zhang, H. Z., Katz, R. L., Hammond, E. H., Fu, K. K., & Milas, L. (2002) · PubMed · Cited by 1,198
Self-citationBrizel, D. M., Albers, M. E., Fisher, S. R., Scher, R. L., Richtsmeier, W. J., Hars, V., George, S. L., Huang, A. T., & Prosnitz, L. R. (1998) · New England Journal of Medicine · doi:10.1056/nejm199806183382503 · Cited by 1,127
Cited by
Items 101–157 of 157
Current trends in initial management of laryngeal cancer: the declining use of open surgery
Silver, C. E., Beitler, J. J., Shaha, A. R., Rinaldo, A., & Ferlito, A. (2009) · European Archives of Oto-Rhino-Laryngology · doi:10.1007/s00405-009-1028-2 · Cited by 345
Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy
Martinelli, E., De Palma, R., Orditura, M., De Vita, F., & Ciardiello, F. (2009) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2009.03992.x · Cited by 333
Focal adhesion signaling and therapy resistance in cancer
Eke, I., & Cordes, N. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2014.07.009 · Cited by 330
Elkabets, M., Pazarentzos, E., Juric, D., Sheng, Q., Pelossof, R. A., Brook, S., Benzaken, A. O., Rodon, J., Morse, N., Yan, J. J., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.010 · Cited by 325
Self-citationBussink, J., van der Kogel, A. J., & Kaanders, J. H. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70073-1 · Cited by 326
Ferris, R. L., Jaffee, E. M., & Ferrone, S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.6360 · Cited by 320
Clinical development of new drug–radiotherapy combinations
on behalf of the NCRI CTRad Academia-Pharma Joint Working Group, Sharma, R. A., Plummer, R., Stock, J. K., Greenhalgh, T. A., Ataman, O., Kelly, S., Clay, R., Adams, R. A., Baird, R. D., et al. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.79 · Cited by 320
Stratigos, A. J., Garbe, C., Dessinioti, C., Lebbe, C., Bataille, V., Bastholt, L., Dreno, B., Concetta Fargnoli, M., Forsea, A. M., Frenard, C., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.01.008 · Cited by 319
Srivastava, R. M., Lee, S. C., Andrade Filho, P. A., Lord, C. A., Jie, H.-B., Davidson, H. C., López-Albaitero, A., Gibson, S. P., Gooding, W. E., Ferrone, S., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2426 · Cited by 318
Current trends in initial management of hypopharyngeal cancer: The declining use of open surgery
Takes, R. P., Strojan, P., Silver, C. E., Bradley, P. J., Haigentz, M., Wolf, G. T., Shaha, A. R., Hartl, D. M., Olofsson, J., Langendijk, J. A., et al. (2012) · Head & Neck · doi:10.1002/hed.21613 · Cited by 312
Skin cancer in solid organ transplant recipients: Advances in therapy and management
O’Reilly Zwald, F., & Brown, M. (2011) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2010.11.062 · Cited by 311
Molecular Imaging–Based Dose Painting: A Novel Paradigm for Radiation Therapy Prescription
Bentzen, S. M., & Gregoire, V. (2011) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2010.10.001 · Cited by 307
Improving head and neck cancer therapies by immunomodulation of the tumour microenvironment
Ruffin, A. T., Li, H., Vujanovic, L., Zandberg, D. P., Ferris, R. L., & Bruno, T. C. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00531-9 · Cited by 305
Integration of EGFR inhibitors with radiochemotherapy
Nyati, M. K., Morgan, M. A., Feng, F. Y., & Lawrence, T. S. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1953 · Cited by 304
Fojo, T., Mailankody, S., & Lo, A. (2014) · JAMA Otolaryngology–Head & Neck Surgery · doi:10.1001/jamaoto.2014.1570 · Cited by 303
Translational genomics and recent advances in oral squamous cell carcinoma
Chai, A. W. Y., Lim, K. P., & Cheong, S. C. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.09.011 · Cited by 298
Modern radiotherapy for head and neck cancer
Alterio, D., Marvaso, G., Ferrari, A., Volpe, S., Orecchia, R., & Jereczek-Fossa, B. A. (2019) · Seminars in Oncology · doi:10.1053/j.seminoncol.2019.07.002 · Cited by 295
Lefebvre, J. L., Rolland, F., Tesselaar, M., Bardet, E., Leemans, C. R., Geoffrois, L., Hupperets, P., Barzan, L., de Raucourt, D., Chevalier, D., et al. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn460 · Cited by 285
Head and Neck Cancers, Version 2.2014
Pfister, D. G., Spencer, S., Brizel, D. M., Burtness, B., Busse, P. M., Caudell, J. J., Cmelak, A. J., Colevas, A. D., Dunphy, F., Eisele, D. W., et al. (2014) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2014.0142 · Cited by 283
Self-citationA Review of HPV-Related Head and Neck Cancer
Kobayashi, K., Hisamatsu, K., Suzui, N., Hara, A., Tomita, H., & Miyazaki, T. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7090241 · Cited by 282
Reconstructing Time-to-event Data from Published Kaplan–Meier Curves
Wei, Y., & Royston, P. (2017) · The Stata Journal: Promoting communications on statistics and Stata · doi:10.1177/1536867x1801700402 · Cited by 282
Managing Premedications and the Risk for Reactions to Infusional Monoclonal Antibody Therapy
Chung, C. H. (2008) · The Oncologist · doi:10.1634/theoncologist.2008-0012 · Cited by 278
Scope, A., Agero, A. L. C., Dusza, S. W., Myskowski, P. L., Lieb, J. A., Saltz, L., Kemeny, N. E., & Halpern, A. C. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.6987 · Cited by 278
Risk factors for osteoradionecrosis after head and neck radiation: a systematic review
Nabil, S., & Samman, N. (2012) · Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology · doi:10.1016/j.tripleo.2011.07.042 · Cited by 277
Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab
Brand, T. M., Iida, M., & Wheeler, D. L. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.11.9.15050 · Cited by 273
Hirsch, F. R., Herbst, R. S., Olsen, C., Chansky, K., Crowley, J., Kelly, K., Franklin, W. A., Bunn, P. A., Varella-Garcia, M., & Gandara, D. R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.0111 · Cited by 271
Cappuzzo, F., Finocchiaro, G., Rossi, E., Jänne, P. A., Carnaghi, C., Calandri, C., Bencardino, K., Ligorio, C., Ciardiello, F., Pressiani, T., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdm492 · Cited by 267
Frederick, B. A., Helfrich, B. A., Coldren, C. D., Zheng, D., Chan, D., Bunn, P. A., & Raben, D. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0138 · Cited by 270
Self-citationJie, H.-B., Schuler, P. J., Lee, S. C., Srivastava, R. M., Argiris, A., Ferrone, S., Whiteside, T. L., & Ferris, R. L. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2788 · Cited by 266
Khambata-Ford, S., Harbison, C. T., Hart, L. L., Awad, M., Xu, L.-A., Horak, C. E., Dakhil, S., Hermann, R. C., Lynch, T. J., & Weber, M. R. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.2890 · Cited by 266
The complexity of targeting EGFR signalling in cancer: From expression to turnover
Sebastian, S., Settleman, J., Reshkin, S. J., Azzariti, A., Bellizzi, A., & Paradiso, A. (2006) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2006.06.001 · Cited by 260
Ang, K. K., & Sturgis, E. M. (2012) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2011.12.004 · Cited by 260
Self-citationErjala, K., Sundvall, M., Junttila, T. T., Zhang, N., Savisalo, M., Mali, P., Kulmala, J., Pulkkinen, J., Grenman, R., & Elenius, K. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2404 · Cited by 259
Harrington, K. J., Hingorani, M., Tanay, M. A., Hickey, J., Bhide, S. A., Clarke, P. M., Renouf, L. C., Thway, K., Sibtain, A., McNeish, I. A., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0196 · Cited by 259
Omura, K. (2014) · International Journal of Clinical Oncology · doi:10.1007/s10147-014-0689-z · Cited by 257
Kitamura, N., Sento, S., Yoshizawa, Y., Sasabe, E., Kudo, Y., & Yamamoto, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010240 · Cited by 256
Perineural Invasion and Perineural Tumor Spread in Head and Neck Cancer
Bakst, R. L., Glastonbury, C. M., Parvathaneni, U., Katabi, N., Hu, K. S., & Yom, S. S. (2019) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2018.12.009 · Cited by 254
Targeted therapy for head and neck cancer: signaling pathways and clinical studies
Li, Q., Tie, Y., Alu, A., Ma, X., & Shi, H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01297-0 · Cited by 253
Head and neck cancer: An evolving treatment paradigm
Cognetti, D. M., Weber, R. S., & Lai, S. Y. (2008) · Cancer · doi:10.1002/cncr.23654 · Cited by 253
Kies, M. S., Holsinger, F. C., Lee, J. J., William, W. N., Glisson, B. S., Lin, H. Y., Lewin, J. S., Ginsberg, L. E., Gillaspy, K. A., Massarelli, E., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.0425 · Cited by 253
Self-citationBiology of Interactions: Antiepidermal Growth Factor Receptor Agents
Harari, P. M., Allen, G. W., & Bonner, J. A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.8984 · Cited by 214
Self-citationLee, S. C., Srivastava, R. M., López-Albaitero, A., Ferrone, S., & Ferris, R. L. (2011) · Immunologic Research · doi:10.1007/s12026-011-8231-0 · Cited by 156
“Various lines of evidence indicate that rituximab (anti-CD20), trastuzumab (anti-HER2), and cetuximab (anti-HER1/anti-EGFR) are used in lymphoma, breast cancer, head and neck, and colorectal carcinomas, respectively (Table 1), and the activities are enhanced by the combination of chemotherapy or radiotherapy [2–10].”
BackgroundGow, C.-H., Chien, C.-R., Chang, Y.-L., Chiu, Y.-H., Kuo, S.-H., Shih, J.-Y., Chang, Y.-C., Yu, C.-J., Yang, C.-H., & Yang, P.-C. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1468 · Cited by 146
Ocular Toxicity of Targeted Therapies
Renouf, D. J., Velazquez-Martin, J. P., Simpson, R., Siu, L. L., & Bedard, P. L. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.5851 · Cited by 139
Cho, J., Chen, L., Sangji, N., Okabe, T., Yonesaka, K., Francis, J. M., Flavin, R. J., Johnson, W., Kwon, J., Yu, S., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1145 · Cited by 117
“Cetuximab (Erbitux) is a human-mouse chimeric monoclonal antibody that is FDA-approved for treatment of colorectal and head and neck cancer patients (14-17).”
BackgroundKaramboulas, C., Bruce, J. P., Hope, A. J., Meens, J., Huang, S. H., Erdmann, N., Hyatt, E., Pereira, K., Goldstein, D. P., Weinreb, I., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.10.004 · Cited by 94
Garrido, G., Rabasa, A., Sánchez, B., López, M. V., Blanco, R., López, A., Hernández, D. R., Pérez, R., & Fernández, L. E. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003477 · Cited by 91
Hofheinz, R.-D., Deplanque, G., Komatsu, Y., Kobayashi, Y., Ocvirk, J., Racca, P., Guenther, S., Zhang, J., Lacouture, M. E., & Jatoi, A. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0051 · Cited by 88
Luedke, E., Jaime-Ramirez, A. C., Bhave, N., Roda, J., Choudhary, M. M., Kumar, B., Teknos, T. N., & Carson, W. E. (2012) · Surgery · doi:10.1016/j.surg.2012.05.035 · Cited by 71
IL-21 Enhances Natural Killer Cell Response to Cetuximab-Coated Pancreatic Tumor Cells
McMichael, E. L., Jaime-Ramirez, A. C., Guenterberg, K. D., Luedke, E., Atwal, L. S., Campbell, A. R., Hu, Z., Tatum, A. S., Kondadasula, S. V., Mo, X., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0004 · Cited by 70
“This regimen led to a significant increase in progression-free survival in colorectal cancer patients and led to complete or partial tumor shrinkage in over 20% of patients (9,10).”
Bourhis, J., Stein, A., Paul de Boer, J., Van Den Eynde, M., Gold, K. A., Stintzing, S., Becker, J. C., Moran, M., Schroeder, A., Pennock, G., et al. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102172 · Cited by 47
Maintenance of Head and Neck Tumor On-Chip: Gateway to Personalized Treatment?
Bower, R., Green, V. L., Kuvshinova, E., Kuvshinov, D., Karsai, L., Crank, S. T., Stafford, N. D., & Greenman, J. (2017) · Future Science OA · doi:10.4155/fsoa-2016-0089 · Cited by 38
Kasper, S., Breitenbuecher, F., Reis, H., Brandau, S., Worm, K., Köhler, J., Paul, A., Trarbach, T., Schmid, K. W., & Schuler, M. (2013) · Oncogene · doi:10.1038/onc.2012.302 · Cited by 35
Immunotherapies targeting tumor vasculature: challenges and opportunities
Dianat-Moghadam, H., Nedaeinia, R., Keshavarz, M., Azizi, M., Kazemi, M., & Salehi, R. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1226360 · Cited by 36
Belgioia, L., Desideri, I., Errico, A., Franzese, C., Daidone, A., Marino, L., Fiore, M., Borghetti, P., Greto, D., & Fiorentino, A. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.11.009 · Cited by 35
Review of clinical applications of radiation-enhancing nanoparticles
Scher, N., Bonvalot, S., Le Tourneau, C., Chajon, E., Verry, C., Thariat, J., & Calugaru, V. (2020) · Biotechnology Reports · doi:10.1016/j.btre.2020.e00548 · Cited by 35
Huang, F., Xu, L.-A., & Khambata-Ford, S. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1135 · Cited by 33
Metadata
- Authors
- Bonner, J. A., Harari, P. M., Giralt, J., Azarnia, N., Shin, D. M., Cohen, R. B., Jones, C. U., Sur, R., Raben, D., Jassem, J., Ove, R., Kies, M. S., Baselga, J., Youssoufian, H., Amellal, N., Rowinsky, E. K., & Ang, K. K.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-02-09
- Volume
- 354
- Issue
- 6
- Pages
- 567-578
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2155384808
- Cited by
- 5,115
- References
- 35
- FWCI
- 341.07
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.